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Abstract
Background: Among patients with type 2 diabetes, insulin intensification to achieve glycemic targets occurs less
often than clinically indicated. Barriers to intensification are not well understood. We present patients’ baseline
characteristics from MOSAIc, a study investigating patient-, physician-, and healthcare environment-based factors
affecting insulin intensification and subsequent health outcomes.
Methods: MOSAIc is a longitudinal, observational study following patients’ diabetes care in 18 countries: United
Arab Emirates (UAE), Argentina, Brazil, Canada, China, Germany, India, Israel, Italy, Japan, Mexico, Russia, Saudi Arabia,
South Korea, Spain, Turkey, United Kingdom, United States. Eligible patients are age ≥18, have type 2 diabetes, and
have used insulin for ≥3 months with/without other antidiabetic medications. Extensive baseline demographic,
clinical, and psychosocial data are collected at baseline and regular intervals during the 24-month follow-up. We
conducted descriptive analyses of baseline data.
Results: Four thousand three hundred forty one patients met eligibility criteria. Patients received their type 2 diabetes
diagnosis 12 ± 8 years prior to baseline visit, yet patients in developing countries were younger than in developed countries
(e.g., UAE, 55 ± 10; Germany = 70 ± 10). Saudi Arabians had the highest HbA1c values (9.0 ± 2.2) and Germany (7.5 ± 1.4)
among the lowest. Most patients in 5 (28 %) of the 18 countries did not use an oral antidiabetic drug. Over half of patients
in fourteen (78 %) countries exclusively used basal insulin; most Indian and Chinese patients exclusively used mixed insulin.
Conclusions: MOSAIc’s baseline data highlight differences in patient characteristics across countries. These patterns, along
with physician and healthcare environment differences, may contribute to the likelihood of insulin intensification and
subsequent clinical outcomes.
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Background
Both the global incidence and prevalence of type 2
diabetes are increasing rapidly, and cases are expected
to reach 329 million by 2030 [1]. The most striking
increases have been in developing countries. In Saudi
Arabia today, 24 % of citizens have type 2 diabetes, a
10-fold increase in prevalence since 1982 [2, 3].
Current type 2 diabetes prevalence exceeds 8 % in
Brazil, China, India, and the Russian Federation, and
exceeds 12 % in Mexico, Turkey, and the United Arab
Emirates [4]. The morbidity and mortality burden as
well as the economic toll associated with type 2 dia-
betes are substantial. Type 2 diabetes is a major risk
factor for heart disease and stroke and the fifth lead-
ing cause of death worldwide [5–7]. In the U.S. alone,
type 2 diabetes-related health expenditures exceeded
$174 billion in 2007, with 1/3 of those expenditures,
$58 billion, spent on preventable complications [8].
Anti-hyperglycemic medications can effectively reduce
blood glucose levels and prevent or forestall diabetes-
related complications, yet poor disease control is com-
mon, especially when patients’ progressive disease merits
the addition of insulin therapy [9–12]. Among the bar-
riers to insulin initiation and glycemic control are pa-
tients’ injection fears and perceived social stigma;
providers’ concerns about hypoglycemia, weight gain,
and patients’ ability to follow more complex regimens;
and health system factors, such as patients’ out-of-
pocket costs for and access to medications [12–17]. Pre-
liminary cross-sectional evidence suggests that barriers
to and facilitators for insulin intensification, e.g., adding
bolus doses and/or increasing injection frequency, are
distinct from those for insulin initiation. At present,
there is no longitudinal evidence to identify and quantify
barriers to insulin intensification. Because many patients’
glycemic levels merit such intensification to achieve gly-
cemic targets over time, these barriers must be enumer-
ated and addressed [5, 18–20].
The 2-year, longitudinal MOSAIc (Multinational
Observational Study Assessing Insulin use: under-
standing the challenges associated with progression of
therapy) study was designed to identify patient, phys-
ician, and health system factors that influence insulin
intensification among patients with type 2 diabetes
and to quantify the relationships between these fac-
tors and long-term clinical outcomes [21]. In this
paper, we describe and explore the heterogeneity of
baseline demographic, clinical, and psychosocial char-
acteristics among 4,341 MOSAIc patients enrolled in
18 different countries. These data provide a unique,
holistic glimpse into the clinical and psychosocial ex-
perience of patients with type 2 diabetes worldwide,
and lay the foundation for MOSAIc’s longitudinal
analyses.
Research design and methods
Study design
The design of, study population, and data collection for
the MOSAIc study have been described extensively [21].
In brief, MOSAIc is a 2-year, longitudinal observational
study that follows patients’ real world diabetes care and
health outcomes. MOSAIc involves no additional treat-
ments, visits, or laboratory collections beyond those oc-
curring within the course of normal care. Data collection
occurs during an initial baseline visit and during four sub-
sequent prospective visit windows (within ±3 months) at
6, 12, 18, and 24 months. At present, only baseline data
are available for all patients.
Study population
MOSAIc has enrolled 4,519 patients from primary care
or specialty practice sites across 18 countries [United
Arab Emirates (UAE), Argentina, Brazil, Canada, China,
Germany, India, Israel, Italy, Japan, Mexico, Russia,
Saudi Arabia, South Korea, Spain, Turkey, United King-
dom (UK), United States including Puerto Rico (US)].
These participating countries were chosen based on geo-
graphic region, population aged 20–79, and the T2DM
prevalence in each region and country [21]. These coun-
tries have heterogeneous levels of economic develop-
ment, industrialization, and healthcare accessibility [22]
and represent 5 global regions: Asia (China, India, Japan,
South Korea), Europe (Germany, Italy, Russia, Spain,
UK), North America (Canada, US), Middle East/North
Africa (Israel, Saudi Arabia, Turkey, UAE), South/Cen-
tral America (Argentina, Brazil, Mexico). Patients were
recruited from two types of clinics, primary care prac-
tices and diabetes specialty clinics, to be representative
of each participating country’s diabetic patient popula-
tion. In addition, we included sites in both rural and
urban locations and academic and non-academic settings.
Clinicians treating enrolled patients have also contributed
demographic data and patient-specific treatment goals at
baseline. MOSAIc-eligible patients were 1) age ≥ 18; 2)
taking any commercially-available insulin therapy other
than intensive basal-bolus insulin therapy (i.e., basal + 3
prandial injections) from any manufacturer for ≥ 3 months
with or without any combination of approved non-insulin
antidiabetic medications; 3) were not simultaneously par-
ticipating in a study that includes an investigational drug
or procedure; and 4) were proficient in the country’s pri-
mary language [21]. All enrolled patients gave docu-
mented consent. Due to inconsistent and poor data
quality, 2 practice sites have been closed since the study
began. Data from these sites were excluded from analyses
in the present manuscript (Fig. 1). Institutional Review
Board approvals were obtained in all countries [21]. The
Institutional Review Board of the Brigham and Women’s
Hospital, the data coordinating center for the entire
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MOSAIc study, deemed the study’s analytic plan as ex-
empt from review. A list of the ethics review boards for all
countries is provided in Additional file 1.
Baseline data collection
Each patient’s available type 2 diabetes clinical history,
including diagnosis date, treatment and complications,
and medication history, was assessed retrospectively
from the practice site’s medical record. Type 2 diabetes-
related health care resource utilization (physician visits,
hospitalizations, and auxiliary provider visits: diabetes
educators, ophthalmologists, podiatrists, cardiologists,
dietitians, and nephrologists), most recent recorded la-
boratory, biometric, and vital sign values, and other co-
morbidities were also assessed, but limited to the period
6 months prior to the baseline visit. Patients’ type 2 dia-
betes medication regimen at the time of the baseline
visit, including medication name, dose, frequency of use,
method of administration (oral, syringe, pen, or pump)
were collected. Finally, each patient’s physician reported
an HbA1c goal for him/her.
Extensive information on patients’ diabetes—and
insulin-related knowledge, attitudes, and behaviors;
hypoglycemia and fasting; general health behaviors;
patient-provider relationships; and perceived physical
and psychological well being were collected at baseline
using self-report questionnaires. In this paper, we focus
on 3 of these validated surveys. The Diabetes Knowledge
Test examines patients’ understanding of their disease,
such as how to manage insulin use and how to treat
hypoglycemia, with a summary score ranging from 0 (no
questions correct) to 9 (all correct) [23]. The 17-item
Diabetes Distress Scale asks patients to indicate to what
degree aspects of their type 2 diabetes treatment and
care are of concern, using a 6-point Likert scale ranging
from “Not a problem” to “A very serious problem [24].”
The summary score ranges from 17 (no distress) to 102
(severe distress). The 25-item Interpersonal Processes of
Care survey measures patients’ perceived quality of their
relationship with their providers; scores range from 1
(poor relationship) to 5 (good relationship) [25]. We also
examined a single question regarding self-monitoring of
blood glucose from the Summary of Diabetes Self-Care
Activities questionnaire: “On how many of the last seven
days did you test your blood sugar the number of times
recommended by your health-care provider?”; responses
ranged from 0 to 7 [26].
Statistical analyses
From the collected data, we created several additional
variables of interest. The first was the summed injection
frequency across insulin medications; if insulin injection
frequency was missing, a once daily frequency was as-
sumed. If method of insulin administration was missing,
we assumed that a syringe was used. We classified pa-
tients as using a syringe, pen, or pump for insulin ad-
ministration; syringe was reported if multiple methods
were used (i.e., syringe and pen or syringe and pump).
Only 12 patients were using an insulin pump alone;
these patients’ insulin administration type was excluded
from the present analysis.
We performed descriptive analyses (mean ± standard
deviation for continuous data; number and percentage
for categorical data) for baseline variables of interest, for
all patients and then by individual country. Due to the
observational nature of the MOSAIc study, baseline data
were not available for all patients for all variables of
interest. The median proportion of missing data for any
one variable was 4.9 %, interquartile range, 3.6–7.8 %.
Patterns of missingness appeared to vary by country.
Based on these facts, we used two approaches in our
analyses. In the first, a “complete case” analysis, we cal-
culated the descriptive measure among those patients
for whom a value was present for a given variable of
interest. Our second approach used multiple imputation
via chained equations to accommodate continuous as
well as categorical variables [27]. Ten imputed datasets
were created. The multiple imputation models included
all variables of interest for which complete data were
available as well as indicator variables for each country
to account for country-specific variation. Imputation
was done for the variable with the smallest proportion of
missingness first and then in order of increasing miss-
ingness for other variables with missing data. To report
descriptive statistics using the imputation approach, cat-
egorical and continuous values were converted to the
log scale to approximate a normal distribution, averaged
across the 10 imputed datasets, and then converted back
to the linear scale; therefore, values and proportions for
each level of the categorical values may not sum to the
total number of patients or to 100 %. All analyses were
Patients with documented consent
N = 4,515
Age 18 at baseline visit
N = 4,501
Age < 18 at baseline visit
N = 14




No insulin use reported for day prior to 
baseline visit
N = 25




Patients taking insulin at baseline visit
N = 4,476





Fig. 1 CONSORT diagram for MOSAIc baseline analytic population
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performed using SAS 9.3 (SAS Institute; Cary, NC) and
Stata 13 (StataCorp LP; College Station, TX).
Results
Among 4,519 patients with baseline data, 4,341 met all
MOSAIc eligibility criteria and comprised the analytic
population (Fig. 1). The most common exclusion was
patients’ use of four or more insulin injections per day,
N = 92 (2 %). Because results using the complete case
analytic approach were similar to those using multiple
imputation, and space constraints preclude presenting
results for all 18 countries, our manuscript tables
present multiple imputation results for 7 countries that
represent developed and developing economies, large
patient populations, and varied races, ethnicities, and
geographic regions (China, India, Mexico, Germany, the
Russian Federation, Saudi Arabia, and the US). Multiple
imputation results for the remaining 11 countries are
presented in supplementary tables found in Online Sup-
plement 2; results from the complete case approach are
also available in the online supplement.
Patients’ demographic characteristics varied signifi-
cantly across countries (Table 1, Additional file 2: Table
S1, S2). UAE (mean age, 55 ± 10) and Saudi Arabian (57
± 10) patients were among the youngest, while German
patients were, on average, 15 years older. 70 % of Rus-
sian patients were female versus only 39 % of Japanese
patients. Few or no patients reported that they were un-
insured in Germany (0 %), the US (5 %), and Israel
(7 %), but 62 % of Italian patients reported having no in-
surance. Current alcohol use was modest in 17 coun-
tries: 5 % (India) – 31 % (Canada); but in the UK, 51 %
reported current use. Current smokers made up 6 % of
Indian versus 22 % of Turkish patients. On average,
MOSAIc patients received their type 2 diabetes diagno-
sis 12 ± 8 years prior to their baseline visit (Table 2,
Additional file 2: Table S3, S4). In 12 of 18 countries, pa-
tients’ mean BMI (kg/m2) was ≥30, indicating obesity; in
the remaining 6 countries, patients’ mean BMI was be-
tween 25 and 29 [28]. Clinically meaningful differences
in baseline HbA1c levels (%) were observed: on average,
patients in Saudi Arabia had the highest HbA1c values
(9.0 ± 2.2) followed closely by Turkey (8.9 ± 2.0);

















N (%) or mean ± SD
Demographics
Age, years 61 ± 11 60 ± 10 70 ± 10 58 ± 10 60 ± 12 64 ± 10 57 ± 10 64 ± 12
Female gender 2176 (50) 209 (56) 69 (46) 405 (44) 117 (57) 168 (70) 135 (60) 284 (53)
Education
<12 grade 1982 (46) 186 (50) 115 (77) 373 (41) 122 (59) 32 (13) 99 (44) 122 (23)
High school graduate or partial college 1327 (31) 132 (35) 20 (13) 203 (22) 41 (20) 92 (38) 56 (25) 270 (50)
≥ College degree 1032 (24) 55 (15) 15 (10) 342 (37) 43 (21) 116 (49) 71 (31) 148 (27)
Marital status
Married or living with a significant other 3490 (80) 342 (92) 107 (72) 860 (94) 154 (75) 167 (69) 177 (78) 355 (66)
Single 851 (20) 31 (8) 42 (28) 58 (6) 52 (25) 73 (31) 49 (22) 185 (34)
Employment
Manual labor 1119 (26) 60 (16) 18 (12) 222 (24) 86 (42) 19 (8) 85 (37) 87 (16)
Professional labor 1358 (31) 161 (43) 23 (16) 284 (31) 59 (29) 135 (56) 83 (37) 178 (33)
Skilled labor 1865 (43) 152 (41) 108 (72) 411 (45) 61 (29) 86 (36) 59 (26) 276 (51)
Insurance type
Private 1010 (23) 38 (10) 1 (1) 299 (33) 33 (16) 6 (3) 2 (1) 343 (63)
Public 2424 (56) 297 (80) 148 (99) 160 (17) 117 (57) 221 (92) 167 (74) 171 (32)
Uninsured 907 (21) 38 (10) 0 (0) 459 (50) 56 (27) 13 (5) 57 (25) 27 (5)
Alcohol consumption
Current 619 (14) 39 (11) 31 (21) 47 (5) 30 (14) 3 (1) 1 (0) 151 (28)
Past 1044 (24) 92 (25) 40 (27) 93 (10) 45 (22) 15 (6) 1 (0) 244 (45)
Smoking status
Current 587 (14) 67 (18) 17 (11) 55 (6) 33 (16) 24 (10) 15 (7) 92 (17)
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N (%) or mean ± SD
Diabetes duration, in years 12 ± 8 11 ± 7 14 ± 8 12 ± 8 13 ± 9 10 ± 7 11 ± 7 13 ± 8
Physician’s HbA1c goal for the patient (%) 6.9 ± 0.6 6.6 ± 0.9 6.9 ± 0.5 6.9 ± 0.5 6.7 ± 0.7 6.7 ± 0.5 7.2 ± 0.4 6.8 ± 0.5
Physician’s HbA1c goal for the patient (mmol/mol) 52 ± 7 49 ± 10 52 ± 6 52 ± 6 50 ± 8 50 ± 6 55 ± 4 51 ± 6
Laboratory values
HbA1c level (%) 8.2 ± 1.8 7.6 ± 1.8 7.5 ± 1.4 8.6 ± 1.7 8.6 ± 2.2 7.7 ± 1.3 9.0 ± 2.2 8.0 ± 1.6
HbA1c level (mmol/mol) 66 ± 20 60 ± 20 58 ± 15 70 ± 19 70 ± 24 61 ± 14 75 ± 24 64 ± 18
Biometric measurements
Systolic blood pressure (mmHg) 132.4 ± 16.2 130.2 ± 15.7 137.9 ± 17.1 131.2 ± 14.5 130.5 ± 17.5 136.3 ± 11.9 134.5 ± 13.3 132.0 ± 18.4
Body mass index (kg/m2) 30 ± 6 25 ± 3 30 ± 5 27 ± 5 28 ± 5 32 ± 5 32 ± 6 34 ± 8
Diabetes-related complications
Amputation 50 (1) 0 (0) 3 (2) 4 (0) 4 (2) 3 (1) 2 (1) 10 (2)
Gastroparesis 111 (3) 11 (3) 2 (1) 7 (1) 3 (2) 18 (8) 24 (11) 13 (2)
Nephropathy 720 (17) 70 (19) 37 (25) 75 (8) 17 (8) 60 (25) 51 (23) 105 (19)
Neuropathy 1280 (29) 118 (32) 57 (38) 224 (24) 50 (24) 155 (65) 90 (40) 216 (40)
Retinopathy 1026 (24) 85 (23) 22 (15) 143 (16) 32 (15) 117 (49) 120 (53) 79 (15)
Diagnostic history of:
Coronary artery disease 808 (19) 75 (20) 30 (20) 105 (11) 3 (2) 132 (55) 59 (26) 140 (26)
Congestive heart failure 244 (6) 21 (6) 19 (13) 19 (2) 3 (1) 81 (34) 5 (2) 34 (6)
Depression 401 (9) 13 (4) 13 (9) 22 (2) 27 (13) 16 (7) 9 (4) 122 (23)
Hypertension 3045 (70) 199 (53) 134 (90) 630 (69) 114 (55) 208 (87) 143 (63) 465 (86)
Hyperlipidemia 2562 (59) 204 (55) 97 (65) 392 (43) 89 (43) 144 (60) 155 (69) 444 (82)
Myocardial infarction 284 (7) 7 (2) 10 (7) 21 (2) 5 (3) 47 (20) 18 (8) 46 (8)












Germany (7.5 ± 1.4) and China (7.6 ± 1.8) had the lowest.
Even though most countries’ patients had poor glycemic
control, there was little variability in their healthcare
providers’ HbA1c goals for them, mean 6.9 ± 0.6. There
were remarkable differences in the prevalence of concur-
rent diagnoses as reported in the medical record: only
2 % of Mexican patients had CAD or CHF, but 55 % of
Russian patients had CAD and 34 % had CHF. Neur-
opathy was present in at least two-fifths of American,
South Korean, Russian, and Saudi Arabian patients, but
more rarely noted in Argentina (9 %) and Spain (12 %).
More than half of patients in China, Mexico, Germany,
Russia and Turkey did not use an oral antidiabetic drug
(Table 3, Additional file 2: Table S5, S6). While more
than two-thirds of patients in Japan, Mexico, Spain, Italy,
Brazil, and Russia exclusively used basal insulin, more
than half of Indian and Chinese patients exclusively used
mixed insulin. Across countries, once daily insulin injec-
tion was most commonly observed; however, in China
and India, twice daily insulin injection was most the
most frequent regimen.
On average, patients’ scores on the Diabetes Knowledge
Test ranged from 3 ± 2 questions (comparatively low
knowledge) correct in South Korea to 7 ± 2 questions cor-
rect in China; scores range from 1 (little or no knowledge)
to 9 (very good knowledge) (Table 4, Additional file 2:
Table S7, S8). Patients’ Diabetes Distress Scale scores
ranged from a mean 24 ± 9 (minimal distress) in Germany
to 55 ± 21 (moderate distress) in Turkey; patients in Brazil
(54 ± 22), Saudi Arabia (51 ± 17) and UAE reported similar
moderate distress. Reported self-monitoring of blood glu-
cose at least once a day over 7 days ranged between 1 ±
2 days in India to 6 ± 2 in Canada. In contrast to the vari-
ation observed for these 2 measures, patients uniformly
reported an ambivalent relationship with their healthcare
providers; the mean score on the Interpersonal Processes
of Care survey in all 18 countries was 3.
Discussion
Among 4,341 patients with type 2 diabetes taking insulin
who are participating in the MOSAIc observational study,
we found substantial variation across patients’ baseline
demographic characteristics, medical history, drug treat-
ment regimens, and self-reported knowledge of and dis-
tress about diabetes. Acknowledging these patient-specific
differences, our aggregate results also showed striking
country-specific differences in patients’ profiles and treat-
ment patterns, offering insight into the healthcare envi-
ronments in each geographic setting. These data also
highlight the complex interplay of demographic, medical
and self-reported data with health status and type 2 dia-
betes treatment and underscore the limitations of a one-
size-fits-all approach to improving type 2 diabetes man-
agement, insulin adherence, and clinical outcomes.




















0 oral antidiabetic drugs 1449 (33) 203 (54) 90 (60) 161 (18) 120 (58) 127 (53) 56 (25) 149 (28)
1 oral antidiabetic drug 1388 (32) 109 (29) 41 (28) 243 (27) 58 (28) 69 (29) 41 (18) 224 (41)
2 oral antidiabetic drugs 977 (23) 52 (14) 14 (9) 282 (31) 21 (10) 37 (15) 78 (35) 132 (24)
3 or more oral antidiabetic drugs 527 (12) 9 (2) 4 (3) 232 (25) 7 (3) 7 (3) 51 (23) 35 (6)
Insulin regimen
Basal insulin only 2234 (51) 60 (16) 65 (44) 252 (27) 146 (71) 197 (82) 140 (62) 355 (66)
Basal + short-acting insulin only 237 (5) 3 (1) 6 (4) 11 (1) 15 (7) 13 (5) 1 (0) 32 (6)
Mixed insulin only 1310 (30) 249 (67) 66 (44) 522 (57) 34 (17) 19 (8) 40 (18) 93 (17)
Short-acting insulin only 175 (4) 13 (4) 5 (3) 43 (5) 9 (4) 10 (4) 0 (0) 20 (4)
Other insulin combinations 385 (9) 48 (13) 7 (5) 90 (10) 2 (1) 1 (0) 45 (20) 40 (7)
Insulin injection frequency
Once per day 2579 (59) 128 (34) 80 (54) 415 (45) 152 (74) 161 (67) 147 (65) 373 (69)
Twice per day 1585 (37) 220 (59) 58 (39) 494 (54) 51 (25) 77 (32) 78 (35) 144 (27)
Three times per day 177 (4) 25 (7) 11 (7) 9 (1) 3 (2) 2 (1) 1 (0) 23 (4)
Insulin delivery device
Pen 3220 (74) 372 (100) 141 (95) 541 (59) 67 (33) 220 (93) 142 (63) 243 (45)
Syringe 1109 (26) 1 (0) 8 (5) 373 (41) 138 (68) 17 (7) 84 (37) 296 (55)
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Age, gender, and disease history are among the stron-
gest predictors of adverse health outcomes. While across
countries, MOSAIc patients had been diagnosed with
type 2 diabetes on average 12 years before study enroll-
ment, potentially because all were using insulin at en-
rollment, it is important to highlight that patients in
developing countries like Brazil, UAE, Saudi Arabia, and
Mexico were still significantly younger at enrollment
than were patients in more developed nations such as
Germany. Type 2 diabetes is a progressive disease, and
as such, an increasingly intensive treatment strategy is
needed to achieve glycemic control over time, with likely
insulin intensification. Because of its prospective, longi-
tudinal design, MOSAIc is well positioned to inform
these treatment progressions and to assess which treat-
ment progression patterns lead to better clinical out-
comes than others. This type of evidence will be of use
when clinical treatment guidelines are updated.
In addition to demographic differences across coun-
tries, we observed significant variation in the report of
diagnoses in patients’ medical records as well as patients’
self-reported type 2 diabetes knowledge and distress.
Variation in the prevalence of reported medical diagno-
ses may be attributable to differences across countries in
the completeness of medical records, providers’ medical
reporting practices, and/or true absence of disease in the
MOSAIc patient population. Because MOSAIc is an ob-
servational study, these potential explanations cannot be
disentangled. Variations in patients’ self-report data may
reflect differences in education, the social acceptability
of acknowledging distress, and the availability of blood
glucose test strips with which to self-monitor glucose
levels. These variations are rooted not only in patients’
heterogeneity, but also in the heterogeneity of the larger
healthcare environment. The documentation of these
differences among patients and across geographic loca-
tions and their relative contributions to type 2 diabetes
outcomes and disease progression may draw healthcare
providers and health policymakers’ attention to their im-
portance and the need to more rigorously record them.
We observed the most striking variation across type 2
diabetes treatment regimens. Oral antidiabetic medica-
tion use, insulin type and injection frequency, and insu-
lin delivery mode all differed by country. While patients’
type 2 diabetes profile certainly plays a role in treatment
planning, it is likely that differences in countries’ health-
care environments account for an important proportion
of the variation we observed. Market penetration of cer-
tain medications versus others, the pricing of medica-
tions, the proportion of patients with insurance, and the
availability of syringes versus pens with which to inject
insulin, and the availability of glucose test strips to de-
termine blood glucose levels may all play a role. Our
planned longitudinal analyses will investigate the contri-
bution of these and other healthcare environment fac-
tors on patients’ treatment regimens and regimen
intensification over time [21]. These analyses and the
role of specific treatment patterns in patients’ adherence
to their type 2 diabetes medication regimens will also in-
form improved educational materials, insulin use train-
ing guides, and care and storage of insulin medications.
The study has several limitations. As an observational
study with a wide breadth and depth of data collection
from both medical records and via self-report, baseline
data were not available for all patients for all variables of
interest. We used multiple imputation with chained equa-
tions, a well-recognized imputation method, which ac-
commodates both categorical and continuous variables, to
impute missing values. This approach assumes that the
missing values are missing at random, but it is not pos-
sible to test this assumption. For these reason, we also
used a complete case analysis approach. Results using the
multiple imputation approach and results using a
complete case approach were quantitatively similar. While
enrolled patients’ demographic, clinical, and psychosocial
characteristics may be different from those of patients
with type 2 diabetes in the general population of each
country [21], we recruited patients from both endocrin-
ology and primary care practice sites with varied practice
locations (urban/rural), size, and practice types (academic/


















Diabetes Knowledge Test scorea 5 ± 2 7 ± 2 6 ± 2 4 ± 2 4 ± 2 6 ± 2 4 ± 2 5 ± 2
Diabetes Distress Scale scoreb 38 ± 19 28 ± 11 24 ± 9 37 ± 19 39 ± 21 49 ± 18 51 ± 17 33 ± 15
Interpersonal Processes of Care scorec 3 ± 0.5 3 ± 0.5 3 ± 0.5 3 ± 0.5 3 ± 0.6 3 ± 0.5 3 ± 0.5 3 ± 0.4
Self-monitoring of blood glucosed 3 ± 3 2 ± 2 5 ± 2 1 ± 2 3 ± 3 4 ± 2 2 ± 2 5 ± 3
a The Diabetes Knowledge Test’s summary score ranges from 0 (no questions correct) to 9 (all questions correct)
b The Diabetes Distress Scale score ranges from 17 (no distress) to 102 (severe distress)
c The Interpersonal Processes of Care score ranges from 1 (poor relationship with healthcare provider) to 5 (good relationship with healthcare provider)
d The self monitoring of blood glucose value ranges from 0 (checked blood glucose on no days of the week as recommended by healthcare provider) to 7
(checked blood glucose on all 7 days of the week as recommended by healthcare provider)
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stand-alone) to maximize generalizability. MOSAIc study
is an observational cohort in which physicians provide
usual care to their patients, reflecting characteristics and
patterns of type 2 diabetes patients and their treatments in
real-world settings. In addition, unlike randomized con-
trolled trials of therapeutic agents, MOSAIc’s exclusion
criteria are not extensive [21]. Ongoing analyses will com-
pare MOSAIc results to results in the general population
in countries where they are available and to results in
other published studies. These comparisons are outside
the scope of the present manuscript.
Conclusion
MOSAIc is the first global study of its kind to collect
and integrate patient-, provider- and healthcare
environment-level factors that may influence patients’
type 2 diabetes treatment regimens and disease course.
The baseline patient characteristics presented here re-
flect the underlying heterogeneity across these levels at
MOSAIc enrollment and hint at the complexity of opti-
mizing patients’ type 2 diabetes disease management
and health outcomes. Longitudinal data collection and
analysis during the 2 years of the MOSAIc study will
help untangle this complexity and contribute to our un-
derstanding and treatment of type 2 diabetes.
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